Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Common Equity (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Common Equity for 13 consecutive years, with $133.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity fell 44.06% year-over-year to $133.0 million, compared with a TTM value of $133.0 million through Sep 2025, down 44.06%, and an annual FY2024 reading of $263.1 million, down 16.11% over the prior year.
  • Common Equity was $133.0 million for Q3 2025 at Tandem Diabetes Care, roughly flat from $133.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $449.6 million in Q2 2022 and bottomed at $133.0 million in Q3 2025.
  • Average Common Equity over 5 years is $311.9 million, with a median of $314.0 million recorded in 2023.
  • The sharpest move saw Common Equity surged 51.28% in 2021, then tumbled 44.06% in 2025.
  • Year by year, Common Equity stood at $433.1 million in 2021, then rose by 1.58% to $439.9 million in 2022, then decreased by 28.71% to $313.6 million in 2023, then dropped by 16.11% to $263.1 million in 2024, then tumbled by 49.46% to $133.0 million in 2025.
  • Business Quant data shows Common Equity for TNDM at $133.0 million in Q3 2025, $133.3 million in Q2 2025, and $155.3 million in Q1 2025.